Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Nature Nanotechnology

Volumn 12, Issue 8, 2017, Pages 763-769

  Yuan, Hengfeng ^a,b   Jiang, Wen ^c   Von Roemeling, Christina A ^b,d   Qie, Yaqing ^b   Liu, Xiujie ^b   Chen, Yuanxin ^b   Wang, Yifan ^e   Wharen, Robert E ^b   Yun, Kyuson ^f   Bu, Guojun ^b   Knutson, Keith L ^b   Kim, Betty Y S ^b  

^a FUDAN UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELL CULTURE; CELL PROLIFERATION; CELLS; DISEASES; TUMORS;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; COLLOIDAL NANOPARTICLES; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2); IMMUNE ACTIVATION; IMMUNE RESPONSE; PROTECTIVE EFFECTS; RECEPTOR LEVELS;

CELL SIGNALING;

CALRETICULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; L SELECTIN; MULTIVALENT BISPECIFIC NANOBIOCONJUGATE ENGAGER; NANOCONJUGATE; NANOPARTICLE; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; MOUSE; NANOMEDICINE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COLLOID; DRUG DELIVERY SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PROCEDURES; THP-1 CELL LINE;

ADAPTIVE IMMUNITY; ANIMALS; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MICE, INBRED BALB C; NANOCONJUGATES; NEOPLASMS; RECEPTOR, ERBB-2; THP-1 CELLS;

EID: 85018454897     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2017.69     Document Type: Article

References (34)

1. Restifo, N. P., Dudley, M. E., Rosenberg, S. A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
2. Bargou, R., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008).
3. Baeuerle, P. A., Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941-4944 (2009).
4. Kalos, M., June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49-60 (2013).
5. Kershaw, M. H., Westwood, J. A., Darcy, P. K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525-541 (2013).
6. Slamon, D. J., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
7. Chao, M. P., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94 (2010).
8. Blattman, J. D., Greenberg, P. D. Cancer immunotherapy: A treatment for the masses. Science 305, 200-205 (2004).
9. Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
10. Garon, E. B., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
11. Motzer, R. J., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
12. Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
13. Nghiem, P. T., et al. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N. Engl. J. Med. 374, 2542-2552 (2016).
14. Topalian, S. L., et al. Safety, activity, immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
15. Li, A. V., et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 5, 204ra130 (2013).
16. Cho, N. H., et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat. Nanotech. 6, 675-682 (2011).
17. Lizotte, P. H., et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotech. 11, 295-303 (2016).
18. Li, H., Li, Y., Jiao, J., Hu, H. M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat. Nanotech. 6, 645-650 (2011).
19. Kalinski, P., et al. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need. Future Oncol. 5, 379-390 (2009).
20. Obeid, M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2006).
21. Jiang, W., Kim, B. Y. S., Rutka, J. T., Chan, W. C. W. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotech. 3, 145-150 (2008).
22. Park, S. G., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160-170 (2010).
23. Ma, Y., et al. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J. Immunol. 90, 5588-5599 (2013).
24. Feng, M., et al. Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk. Proc. Natl Acad. Sci. USA 112, 2145-2150 (2014).
25. Liu, X., et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209-1215 (2015).
26. Klebanoff, C. A., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571-9576 (2005).
27. Gardai, S. J., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-324 (2005).
28. Green, D. R., Ferguson, T., Zitvogel, L., Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353-363 (2009).
29. Mellman, I., Coukos, G., Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
30. Sharma, P., Allison, J. P. The future of immune checkpoint therapy Science 348, 56-61 (2015).
31. Qie, Y., et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci. Rep. 6, 26269 (2016).
32. Jiang, W., Mardyani, S., Fischer, H., Chan, W. C. W. Design and characterization of lysine cross-linked mercapto-acid biocompatible quantum dots. Chem. Mater. 18, 872-878 (2006).
33. Mosser, D. M., Zhang, X. Activation of murine macrophages. Curr. Protocol. Immunol. 83, 14. 2. 1-14. 2. 8 (2008).
34. Weiskopf, K., et al. Engineered SIRP? variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88-91 (2013).